Vera Therapeutics announced positive final results from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in adults with IgA nephropathy, showing significant reductions in proteinuria and kidney disease progression risk. The drug demonstrated a safety profile comparable to placebo, with fewer serious adverse events. These results were presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine. Vera plans to submit for full FDA approval in late 2026, with approval expected in 2027, potentially transforming treatment for this serious kidney disease.
Vera Therapeutics' positive ORIGIN 3 trial results for TRUTAKNA in IgA nephropathy provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 22, 2026 20:11 WIB: out of 150 priced US health-sector stocks, 67 rose and 77 fell. Notable movers include AbCellera Biologics Inc (ABCL) at USD 11.89 with 79% buy order activity, Zimmer Biomet Holdings Inc (ZBH) at USD 97.49 up 2.77%, and AbbVie Inc (ABBV) at USD 277.45 down 2.55% with 63% sell order activity.
The global Urban Air Mobility (UAM) market is projected to grow from $2.16 billion in 2026 to $16.27 billion by 2035, at a CAGR of 20.9%. This growth is fueled by rising urbanization, traffic congestion, and advances in electric vertical takeoff and ...
Scotiabank analyst Nat Schindler set a $650 price target for Meta Platforms, about 6.8% below its then-current price of $697.52. Despite Meta's strong revenue from Facebook, Instagram, and WhatsApp, investor concerns over increased artificial intelli...
UBS maintains a Buy rating on Berkshire Hathaway's Class A shares, currently trading near $811,320. The company's diverse portfolio and substantial cash reserves of about $360 billion provide stability and investment flexibility. Investor confidence ...
Barclays PLC reported Q3 2026 earnings with EPS of $0.66 and revenue of $9.86 billion, both slightly below analyst estimates. Pre-tax profit rose 12% year-over-year to £2.32 billion but missed forecasts due to a 19% decline in fixed-income revenue, p...
Comfort Systems USA is set to report strong Q3 2026 results, with analysts predicting earnings of $12.85 per share and revenue around $3.40 billion, driven by high demand in data centers and a record $14.06 billion backlog. The company showed robust ...
